May 25, 2020
Nippon Boehringer Ingelheim’s tyrosine kinase inhibitor Ofev (nintedanib) has grabbed the nod of a key health ministry panel for an additional indication of progressive fibrosing interstitial lung disease (PF-ILD), setting the stage for its official stamp of approval as early...read more